Stocks and Investing
Stocks and Investing
Fri, November 5, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Anupam Rama Upgraded (TBPH) to Hold and Increased Target to $12 on, Nov 5th, 2021
Anupam Rama of JP Morgan, Upgraded "Theravance Biopharma, Inc." (TBPH) to Hold and Increased Target from $7 to $12 on, Nov 5th, 2021.
Anupam has made no other calls on TBPH in the last 4 months.
There are 5 other peers that have a rating on TBPH. Out of the 5 peers that are also analyzing TBPH, 1 agrees with Anupam's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021
These are the ratings of the 4 analyists that currently disagree with Anupam
- Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $8 on, Thursday, September 16th, 2021
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $10 on, Thursday, September 16th, 2021
- Vikram Purohit of "Morgan Stanley" Maintained at Sell with Decreased Target to $10 on, Thursday, September 16th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021
Contributing Sources